The North American internal neurostimulation devices market is mainly driven by the rapidly aging population and associated diseases like Alzheimer’s, epilepsy, spinal cord injury, and Parkinson’s disease. It is expected to grow at a CAGR of 11.8% in the next five years. This is primarily due to the technical advances and patient-friendly techniques such as minimally invasive and non-invasive. The North American internal neurostimulation market was $2548.27 million in 2013, and is expected to reach $4242.09 million by 2018, at a CAGR of 10.7%.The internal neuromodulation market contributed the largest share of 87% to the overall neurostimulation market.
The report ‘North American Internal Neurostimulation Devices Market forecast, 2012-2018’ analyzes the internal neurostimulation market segmented by modalities including spinal cord stimulation (SCS), deep brain stimulation (DBS), vagus nerve stimulation (VNS), sacral nerve stimulation (SNS), and gastric electrical stimulation (GES). The report includes applications, such as chronic pain, failed back surgery syndrome, refractory angina pectoris, peripheral neuropathy, Alzheimer’s, Dystonia, Tourette’s syndrome, Parkinson’s, epilepsy, fecal incontinence, urine incontinence, and gastroparesis.
These segments are expected to experience a positive growth until 2018, with an increased awareness for procedures and sophisticated diagnostic techniques. With a market value of $2.3 and $0.6 billion, the spinal cord stimulation (SCS) and deep brain stimulation (DBS) segments have been contributing 51% and 14%, in terms of value, towards total internal neurostimulation device market. Both the markets have been witnessing high growth because of increase in patient pool and procedure numbers of spinal cord stimulation (SCS), deep brain stimulation (DBS), vagus nerve stimulation (VNS), sacral nerve stimulation (SNS), and gastric electrical stimulation (GES).
Procedure volume growth is significantly higher in the U.S and Mexico because of fast disease progression, improving healthcare infrastructure, economic growth, broadening insurance coverage, expanding private healthcare sector, and increasing awareness amongst people.
According to the International Neurostimulation Society, about 40 million patients worldwide suffer from epilepsy and 1.5 million from Parkinson’s, in the U.S. alone. A wide pool of patients suffering from other conditions, such as depression, stroke, anxiety disorders, lower back pain, urinary incontinence, and tremor are also an influential factor in triggering the market growth. Treatment for tinnitus represents one of the emerging applications in this market. According to the American Tinnitus Association, about 50 million people in the U.S. suffer from this disease.
The prevalence of Alzheimer’s in Europe and North America is around 6.4-5.4% in adults, whereas in Asia, it is around 4%. The reason for prevalence in Asia is a growth in the aging population, whereas in North America and Europe it’s because of population suffering from diabetes and obesity. The incidence of Alzheimer’s was 411,000 in 2000. This increased to 454,000 in 2010. It is expected to reach 615,000 by 2030 and 959,000 by 2050. Such high incidences rate in neurological disorders will positively affect the market for neuromodulation.
The report also provides an extensive competitive landscaping of companies operating in North American internal neurostimulation market. The key players dominating the internal neurostimulation market include Medtronic, Boston Scientific, St. Jude Medical, Cyberonics, Enteromedics, Neurotech, Cerebomed, Microtransponder, and BioControl Medical.
Segment and country-specific company shares, news & deals, mergers and acquisitions, segment-specific pipeline products, product approvals, and product recalls of the major companies have been detailed.
Along with the market data, you can also customize MMM assessments that meet your company’s specific needs. Customize to get comprehensive industry standard and deep dive analysis of the following parameters:
- Product Analysis
- Usage pattern (in-depth trend analysis) of products (segment wise)
- Product matrix which gives a detailed comparison of product portfolio of each company mapped at country and sub-segment level
- End-user adoption rate analysis of the products (segment wise and country wise)
- Comprehensive coverage of product approvals, pipeline products, and product recalls
- Epidemiology Data
- Country-specific prevalence of Alzheimer’s, Parkinson’s, epilepsy, and stroke
- Country-specific incidence of Alzheimer’s, Parkinson’s, epilepsy, and stroke
- Country-specific mortality rate of stroke and epilepsy
- Country-specific patient pool of Alzheimer’s, Parkinson’s, epilepsy, and stroke
- Disease progression (pattern analysis)
- Procedure Volume Data
- Country-wise number of surgeries for epilepsy, heart failure, Alzheimer’s, and Parkinson’s
- Surgeons/Physicians Perception Analysis
- Fast turn-around analysis of surgeons’ response to market events and trends
- Pattern analysis of usage of spinal cord stimulation (SCS) and deep brain stimulation (DBS) by physicians
- Surgeons’ opinion about products from different companies
- Surgeons’ qualitative inputs on epidemiology data
- Brand/Product Perception Matrix
- Comprehensive study of customers perception and behavior through our inbuilt social connect tool checking the virality and tonality of blogs
- Analysis of overall brand usage and familiarity and brand advocacy distribution (detractor/neutral/familiar)
- Pricing Trends
- Cost analysis of North American internal neurostimulation devices
- Procedural investments in North American internal neurostimulation
- Competitive Intelligence
- The company share analysis of the top players in the North American internal neurostimulation market
- The crucial developments and strategies of companies inculcated in their portfolio of internal neurostimulation
1.1 Introduce the Market
1.2 Objective of the study
1.3 Market Definition and Scope of the study
1.3.1 Market Definition
1.3.2 Areas covered
1.3.3 Markets Covered
1.5 Research Methodology
1.5.1 Secondary sources
1.5.2 Primary Sources
1.5.3 Market estimation methodology (Top-down, bottom-up, data triangulation.)
1.5.4 Macro indicators for the study
1.7 List of Acronyms
2 Market Overview
3 Internal Neurostimulation-North America, By SurgeryProcedures
3.1 Split By Geography
3.2 Internal Neurostimulation-North America-Direct Nerve Repair
3.2.1 Internal Neurostimulation-North America-Direct Nerve Repair, By Geographies
220.127.116.11 Internal Neurostimulation-U.S.-Direct Nerve Repair
18.104.22.168 Internal Neurostimulation-Canada-Direct Nerve Repair
22.214.171.124 Internal Neurostimulation-Mexico-Direct Nerve Repair
3.3 Internal Neurostimulation-Nerve Grafting-North America
3.4 Internal Neurostimulation-Stem cell therapy-North America
4 Internal Neurostimulation-North America, By Types
4.1 Split By Geography
4.2 Spinal cord stimulator-North America
4.2.1 Spinal cord stimulator-North America, By Applications
126.96.36.199 Spinal cord stimulator-Chronic Pain-North America
188.8.131.52 Spinal cord stimulator-Spinal Cord Injury-North America
184.108.40.206 Spinal cord stimulator-Ischemic heart disease-North America
220.127.116.11 Spinal cord stimulator-Others-North America
4.2.2 Spinal cord stimulator-North America, By Geographies
18.104.22.168 Spinal cord stimulator-U.S.
22.214.171.124 Spinal cord stimulator-Canada
126.96.36.199 Spinal cord stimulator-Mexico
4.3 Deep Brain Stimulator-North America
4.3.1 Deep Brain Stimulator-North America, By Applications
188.8.131.52 Deep Brain Stimulator-Parkinson’s Disease-North America
184.108.40.206 Deep Brain Stimulator-Other Applications-North America
220.127.116.11 Deep Brain Stimulator-Coma and Brain Death-North America
18.104.22.168 Deep Brain Stimulator-Depression-North America
4.3.2 Deep Brain Stimulator-North America, By Geographies
22.214.171.124 Deep Brain Stimulator-U.S.
126.96.36.199 Deep Brain Stimulator-Canada
188.8.131.52 Deep Brain Stimulator-Mexico
4.4 Sacral Nerve Stimulator-North America
4.4.1 Sacral Nerve Stimulator-North America, By Applications
184.108.40.206 Sacral Nerve Stimulator-Urine Incontinence-North America
220.127.116.11 Sacral Nerve Stimulator-Fecal Incontinence-North America
4.4.2 Sacral Nerve Stimulator-North America, By Geographies
18.104.22.168 Sacral Nerve Stimulator-U.S.
22.214.171.124 Sacral Nerve Stimulator-Canada
126.96.36.199 Sacral Nerve Stimulator-Mexico
4.5 Vagus Nerve Stimulator-North America
4.5.1 Vagus Nerve Stimulator-North America, By Applications
188.8.131.52 Vagus Nerve Stimulator-Epilepsy-North America
184.108.40.206 Vagus Nerve Stimulator-Other Applications-North America
4.5.2 Vagus Nerve Stimulator-North America, By Geographies
220.127.116.11 Vagus Nerve Stimulator-U.S.
18.104.22.168 Vagus Nerve Stimulator-Canada
22.214.171.124 Vagus Nerve Stimulator-Mexico
4.6 Gastric Electrical stimulator-North America
4.6.1 Gastric Electrical stimulator-North America, By Applications
126.96.36.199 Gastric Electrical stimulator-Gastroparesis-North America
188.8.131.52 Gastric Electrical stimulator-Others-North America
4.6.2 Gastric Electrical stimulator-North America, By Geographies
184.108.40.206 Gastric Electrical stimulator-U.S.
220.127.116.11 Gastric Electrical stimulator-Canada
18.104.22.168 Gastric Electrical stimulator-Mexico
5 Internal Neurostimulation-North America, By Geographies
5.1 Internal Neurostimulation-U.S.
5.1.1 Internal Neurostimulation-U.S., By SurgeryProcedures
22.214.171.124 Internal Neurostimulation-U.S.-Direct Nerve Repair
126.96.36.199 Internal Neurostimulation-U.S.-Nerve Grafting
188.8.131.52 Internal Neurostimulation-U.S.-Stem cell therapy
5.1.2 Internal Neurostimulation-U.S., By Companies
184.108.40.206 Internal Neurostimulation-U.S.-Medtronic, Inc.
220.127.116.11 Internal Neurostimulation-U.S.-St. Jude Medical, Inc.
18.104.22.168 Internal Neurostimulation-U.S.-Boston Scientific
22.214.171.124 Internal Neurostimulation-U.S.-Other Companies
126.96.36.199 Internal Neurostimulation-U.S.-Cyberonics
188.8.131.52 Internal Neurostimulation-U.S.-Biocontrol Medical
184.108.40.206 Internal Neurostimulation-U.S.-Johnson & Johnson
220.127.116.11 Internal Neurostimulation-U.S.-Greatbatch Inc
5.1.3 Internal Neurostimulation-U.S., By Types
18.104.22.168 Spinal cord stimulator-U.S.
22.214.171.124 Deep Brain Stimulator-U.S.
126.96.36.199 Sacral Nerve Stimulator-U.S.
188.8.131.52 Vagus Nerve Stimulator-U.S.
184.108.40.206 Gastric Electrical stimulator-U.S.
5.2 Internal Neurostimulation-Canada
5.2.1 Internal Neurostimulation-Canada, By Companies
220.127.116.11 Internal Neurostimulation-Canada-Medtronic, Inc.
18.104.22.168 Internal Neurostimulation-Canada-St. Jude Medical, Inc.
22.214.171.124 Internal Neurostimulation-Canada-Boston Scientific
126.96.36.199 Internal Neurostimulation-Canada-Cyberonics
188.8.131.52 Internal Neurostimulation-Canada-Other Companies
184.108.40.206 Internal Neurostimulation-Canada-Biocontrol Medical
220.127.116.11 Internal Neurostimulation-Canada-Johnson & Johnson
18.104.22.168 Internal Neurostimulation-Canada-Greatbatch Inc
5.2.2 Internal Neurostimulation-Canada, By SurgeryProcedures
22.214.171.124 Internal Neurostimulation-Canada-Direct Nerve Repair
126.96.36.199 Internal Neurostimulation-Canada-Nerve Grafting
188.8.131.52 Internal Neurostimulation-Canada-Stem cell therapy
5.2.3 Internal Neurostimulation-Canada, By Types
184.108.40.206 Spinal cord stimulator-Canada
220.127.116.11 Deep Brain Stimulator-Canada
18.104.22.168 Sacral Nerve Stimulator-Canada
22.214.171.124 Vagus Nerve Stimulator-Canada
126.96.36.199 Gastric Electrical stimulator-Canada
5.3 Internal Neurostimulation-Mexico
5.3.1 Internal Neurostimulation-Mexico, By Companies
188.8.131.52 Internal Neurostimulation-Mexico-Medtronic, Inc.
184.108.40.206 Internal Neurostimulation-Mexico-Other Companies
220.127.116.11 Internal Neurostimulation-Mexico-St. Jude Medical, Inc.
18.104.22.168 Internal Neurostimulation-Mexico-Boston Scientific
22.214.171.124 Internal Neurostimulation-Mexico-Cyberonics
126.96.36.199 Internal Neurostimulation-Mexico-Biocontrol Medical
188.8.131.52 Internal Neurostimulation-Mexico-Johnson & Johnson
184.108.40.206 Internal Neurostimulation-Mexico-Greatbatch Inc
5.3.2 Internal Neurostimulation-Mexico, By SurgeryProcedures
220.127.116.11 Internal Neurostimulation-Mexico-Direct Nerve Repair
18.104.22.168 Internal Neurostimulation-Mexico-Nerve Grafting
22.214.171.124 Internal Neurostimulation-Mexico-Stem cell therapy
5.3.3 Internal Neurostimulation-Mexico, By Types
126.96.36.199 Spinal cord stimulator-Mexico
188.8.131.52 Deep Brain Stimulator-Mexico
184.108.40.206 Sacral Nerve Stimulator-Mexico
220.127.116.11 Vagus Nerve Stimulator-Mexico
18.104.22.168 Gastric Electrical stimulator-Mexico
6 Internal Neurostimulation-North America, By Companies
6.1 Split By Geography
6.2 Internal Neurostimulation-North America-Medtronic, Inc.
6.2.1 Internal Neurostimulation-North America-Medtronic, Inc., By Geographies
22.214.171.124 Internal Neurostimulation-U.S.-Medtronic, Inc.
126.96.36.199 Internal Neurostimulation-Canada-Medtronic, Inc.
188.8.131.52 Internal Neurostimulation-Mexico-Medtronic, Inc.
6.3 Internal Neurostimulation-North America-St. Jude Medical, Inc.
6.3.1 Internal Neurostimulation-North America-St. Jude Medical, Inc., By Geographies
184.108.40.206 Internal Neurostimulation-U.S.-St. Jude Medical, Inc.
220.127.116.11 Internal Neurostimulation-Canada-St. Jude Medical, Inc.
18.104.22.168 Internal Neurostimulation-Mexico-St. Jude Medical, Inc.
6.4 Internal Neurostimulation-North America-Boston Scientific
6.4.1 Internal Neurostimulation-North America-Boston Scientific, By Geographies
22.214.171.124 Internal Neurostimulation-U.S.-Boston Scientific
126.96.36.199 Internal Neurostimulation-Canada-Boston Scientific
188.8.131.52 Internal Neurostimulation-Mexico-Boston Scientific
6.5 Internal Neurostimulation-North America-Other Companies
6.5.1 Internal Neurostimulation-North America-Other Companies, By Geographies
184.108.40.206 Internal Neurostimulation-U.S.-Other Companies
220.127.116.11 Internal Neurostimulation-Canada-Other Companies
18.104.22.168 Internal Neurostimulation-Mexico-Other Companies
6.6 Internal Neurostimulation-North America-Cyberonics
6.6.1 Internal Neurostimulation-North America-Cyberonics, By Geographies
22.214.171.124 Internal Neurostimulation-U.S.-Cyberonics
126.96.36.199 Internal Neurostimulation-Canada-Cyberonics
188.8.131.52 Internal Neurostimulation-Mexico-Cyberonics
6.7 Internal Neurostimulation-North America-Biocontrol Medical
6.7.1 Internal Neurostimulation-North America-Biocontrol Medical, By Geographies
184.108.40.206 Internal Neurostimulation-U.S.-Biocontrol Medical
220.127.116.11 Internal Neurostimulation-Canada-Biocontrol Medical
18.104.22.168 Internal Neurostimulation-Mexico-Biocontrol Medical
6.8 Internal Neurostimulation-North America-Johnson & Johnson
6.8.1 Internal Neurostimulation-North America-Johnson & Johnson, By Geographies
22.214.171.124 Internal Neurostimulation-U.S.-Johnson & Johnson
126.96.36.199 Internal Neurostimulation-Canada-Johnson & Johnson
188.8.131.52 Internal Neurostimulation-Mexico-Johnson & Johnson
6.9 Internal Neurostimulation-North America-Greatbatch Inc
6.9.1 Internal Neurostimulation-North America-Greatbatch Inc, By Geographies
184.108.40.206 Internal Neurostimulation-U.S.-Greatbatch Inc
220.127.116.11 Internal Neurostimulation-Canada-Greatbatch Inc
18.104.22.168 Internal Neurostimulation-Mexico-Greatbatch Inc
Please fill in the form below to receive a free copy of the Summary of this Report
Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
Asian Neurostimulation/Neuromodulation devices Market
The Asian Neurostimulation/Neuromodulation market was expected to reach from $415.32 million in 2013 to $777.62 million by 2018 at a CAGR of 13.4%. The market divided by 2 segments such as Internal Neuromodulation and External Neuromodulation. The internal neuromodulation devices market includes spinal cord stimulation (SCS), deep brain stimulation (DBS), vagus nerve stimulation (VNS), sacral nerve stimulation (SNS), gastric electrical stimulation (GES), and external neuromodulation devices such as transcranial magnetic stimulation (TMS) and transcutaneous electrical nerve stimulation (TENS). Major players in the market include Medtronic, Inc. (U.S.), Cyberonics, Inc. (U.S.), Boston Scientific Corp. (U.S.), St. Jude Medical, Inc. (U.S.), Enteromedics, Inc. (U.S.), Dynatronics Corp. (U.S.), and Neuronetics (U.S.).
European Neurostimulation/Neuromodulation Devices Market
The report also provides a detailed competitive landscaping of companies operating in this market. Segment- and country-specific company shares, news & deals, M&A, segment-specific pipeline products, product approvals, and product recalls of major companies are detailed in the report. Boston Scientific (U.S.), Cyberonics (U.S), Medtronic, Inc. (U.S.), Depuy Synthes (Johnson & Johnson) (U.S.), and St. Jude Medical Inc. (U.S.) are some of the key players engaged in this market.
North America Internal Neuromodulation Devices Market
The North America neuromodulation market has been segmented by procedure, modality, and geography. On the basis of procedure, the market is further segmented into internal and external stimulation. The internal stimulation segment accounted for a share of 87.4% in the neuromodulation market. The market based on modality covers internal and external modality. The internal modality segment accounted for a share of 85.9% in the neuromodulation market.